Published on
December 30, 2020

Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club

Mind Cure's nootropic products are set to launch across 17 locations within North America starting Feb, 2021.

VANCOUVER, BC, Dec. 31, 2020 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("Mind Cure" or the "Company") is pleased to announce that Mind Cure's three nootropic supplements, Focus, Energy, and Immunity, will be available in Body Energy Club locations to provide customers with a tactile, in-store shopping experience. Body Energy Club carries one of the widest varieties of high-quality supplements for individuals seeking to achieve peak performance.

"We are thrilled that Mind Cure's line of nootropic supplements will be joining the extensive array of wellness supplements offered at Body Energy Club. While we ready the release of our online store, we're eager for our wellness products to be made available for in-person purchase as well, starting in one of the most health-conscious area codes in the country," said Kelsey Ramsden, President & CEO, Mind Cure.

About Body Energy Club

Body Energy Club was established in 2002, beginning with one store on Davie Street in Vancouver and growing to 17 locations (including franchises) in Vancouver and LA. Body Energy Club offers all-natural supplements and smoothies that promote overall health, weight loss, and brain function. Body Energy Club's original goal and founding principles involve making healthy lifestyle choices available and affordable for everyone by offering the widest selection of health products at the lowest possible price.

"We believe Mind Cure's focus on mental hygiene and wellness aligns well with our core values at Body Energy Club. We pride ourselves on carrying the best-in-class supplements at affordable prices. Mind Cure's line of functional mushrooms provide the kind of quality and careful formulation that our customers care about," said Grayson Williams, Co-Owner, Body Energy Club.

About Mind Cure's Nootropics

Mind Cure harnesses the benefits of nootropic mushrooms, which can promote daily mental hygiene and cognitive function. Mind Cure's current line of supplements include three functional mushroom-based nootropics (in powder and capsule form): Lion's Mane Focus, to enhance focus; Reishi Energy, to improve sleep & generate energy; and Turkey Tail Immunity, to promote immune-system function. Mind Cure sources fruiting bodies from purely organic farms in California, and sources mycelium from organic Canadian grains. Mind Cure continues to expand its nootropic products as the company discovers new potential through research and shifting regulations, identifying, and perfecting natural products that can help people achieve their best selves.

Mind Cure's current line of nootropics will be available for pre-order mid-January on our company website

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Philip Tapley, Chairman
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure's three nootropic supplements, Focus, Energy, and Immunity, becoming available at Body Energy Club locations; and Mind Cure continuing to expand its nootropic products as the Company discovers new potential through research and shifting regulations, identifying, and perfecting natural products.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure's business; there will be a demand for Mind Cure's products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that Body Energy Club will be a successful reseller of Mind Cure's nootropic products; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure's industry and Mind Cure's business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure's investments, results of operations, financial condition, and Mind Cure's ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; that Body Energy Club may not be a successful reseller of Mind Cure's nootropic products; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under "Risk Factors" in Mind Cure's final prospectus which is available on SEDAR at

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory

The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.